Literature DB >> 17435968

Prognostic factors in Vogt-Koyanagi-Harada disease.

Abdullah S Al-Kharashi1, Hassan Aldibhi, Hamad Al-Fraykh, Dustan Kangave, Ahmed M Abu El-Asrar.   

Abstract

PURPOSE: To identify prognostic factors for final visual outcome, development of complications, and recurrent inflammation in patients with Vogt-Koyanagi-Harada (VKH) disease.
METHODS: All patients diagnosed with acute uveitis associated with VKH disease at the King Khaled Eye Specialist Hospital and King Abdulaziz University Hospital between January 1999 and February 2004 were reviewed. Data collected included age, gender, initial and final visual acuities, clinical findings at presentation, interval between onset of disease and starting treatment, treatment received, complications, number of recurrences, extraocular manifestations, and duration of follow-up period.
RESULTS: Sixty-eight patients were identified. There were 51 (75%) females and 17 (25%) males with a mean age of 25.04 +/- 10.28 years (range 7-55 years). The mean follow-up period was 34.4 +/- 20.1 months (range 8-62 months). The following factors were significantly associated with final visual acuity of 20/20 by univariate analysis: good initial visual acuity of better than 20/200 (p = 0.0415), absence of posterior synechiae of the iris at presentation (p = 0.0106), use of systemic corticosteroids for longer than nine months (p = 0.0479), slow tapering of systemic corticosteroids (p = 0.0024), absence of complications (p < 0.001), and absence of extraocular manifestations (p = 0.0124). Logistic regression analysis identified the use of systemic corticosteroids for longer than nine months to be associated with final visual acuity of 20/20 [odds ratio = 3.4; 95% confidence interval (CI) = 1.14-10.1]. The following factors were significantly associated with the development of complications by univariate analysis: age older than 18 years (p = 0.0161), initial visual acuity of 20/200 or worse (p = 0.0011), and presence of posterior synechiae of the iris at presentation (p = 0.0453). Factors identified after logistic regression analyses were age older than 18 years (odds ratio = 3.3; 95% CI = 1.33-8.17), and presence of posterior synechiae of the iris at presentation (odds ratio = 3.42; 9% CI = 1.38-8.47). Initial visual acuity of better than 20/200 was significantly associated with a lower risk of developing complications (odds ratio = 0.283; 95% CI = 0.129-0.629). The following factors were significantly associated with recurrent inflammation of three times or more by univariate analysis: initial visual acuity of 20/200 or worse (p = 0.0179), anterior chamber reaction of more than 2+ at presentation (p < 0.001), rapid tapering of systemic corticosteroids (p < 0.001), and development of extraocular manifestations (p = 0.0277).
CONCLUSIONS: Clinical findings at presentation, duration and method of tapering of systemic corticosteroids, and development of extraocular manifestations are significantly associated with final visual acuity, development of ocular complications, and recurrent inflammation. The development of ocular complications was significantly associated with a worse final visual acuity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17435968     DOI: 10.1007/s10792-007-9062-9

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.029


  21 in total

1.  Ocular and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in Lewis rats.

Authors:  K Yamaki; I Kondo; H Nakamura; M Miyano; S Konno; S Sakuragi
Journal:  Exp Eye Res       Date:  2000-10       Impact factor: 3.467

2.  Vogt-Koyanagi-Harada syndrome.

Authors:  S Ohno; D H Char; S J Kimura; G R O'Connor
Journal:  Am J Ophthalmol       Date:  1977-05       Impact factor: 5.258

3.  Subretinal fibrosis in patients with Vogt-Koyanagi-Harada disease.

Authors:  I C Kuo; A Rechdouni; N A Rao; R H Johnston; T P Margolis; E T Cunningham
Journal:  Ophthalmology       Date:  2000-09       Impact factor: 12.079

4.  Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease.

Authors:  K Yamaki; K Gocho; K Hayakawa; I Kondo; S Sakuragi
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

5.  Complications and prognostic factors in Vogt-Koyanagi-Harada disease.

Authors:  R W Read; A Rechodouni; N Butani; R Johnston; L D LaBree; R E Smith; N A Rao
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

6.  Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome.

Authors:  P E Rubsamen; J D Gass
Journal:  Arch Ophthalmol       Date:  1991-05

7.  Subretinal neovascular membranes in Vogt-Koyanagi-Harada syndrome.

Authors:  R S Moorthy; L P Chong; R E Smith; N A Rao
Journal:  Am J Ophthalmol       Date:  1993-08-15       Impact factor: 5.258

8.  Incidence and management of cataracts in Vogt-Koyanagi-Harada syndrome.

Authors:  R S Moorthy; B Rajeev; R E Smith; N A Rao
Journal:  Am J Ophthalmol       Date:  1994-08-15       Impact factor: 5.258

Review 9.  Vogt-Koyanagi-Harada syndrome in children.

Authors:  S R Rathinam; P Vijayalakshmi; P Namperumalsamy; R A Nozik; E T Cunningham
Journal:  Ocul Immunol Inflamm       Date:  1998-09       Impact factor: 3.070

10.  Clinical studies of Vogt-Koyanagi-Harada's disease.

Authors:  S Ohno; R Minakawa; H Matsuda
Journal:  Jpn J Ophthalmol       Date:  1988       Impact factor: 2.447

View more
  14 in total

1.  High rate of clinical recurrence in patients with Vogt-Koyanagi-Harada disease treated with early high-dose corticosteroids.

Authors:  Viviane M Sakata; Felipe T da Silva; Carlos E Hirata; Maria Lucia C Marin; Helcio Rodrigues; Jorge Kalil; Rogerio A Costa; Joyce H Yamamoto
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-01-16       Impact factor: 3.117

2.  Incidence and clinical features of recurrent Vogt-Koyanagi-Harada disease in Japanese individuals.

Authors:  Chiharu Iwahashi; Kensuke Okuno; Noriyasu Hashida; Kei Nakai; Nobuyuki Ohguro; Kohji Nishida
Journal:  Jpn J Ophthalmol       Date:  2015-03-26       Impact factor: 2.447

3.  High prevalence of angle-closure glaucoma in Vogt-Koyanagi-Harada disease.

Authors:  Carlos Alvarez-Guzman; Jorge E Valdez-Garcia; Raul E Ruiz-Lozano; Alejandro Rodriguez-Garcia; Carlos F Navas-Villar; Curt Hartleben-Matkin; Miguel Pedroza-Seres
Journal:  Int Ophthalmol       Date:  2022-07-05       Impact factor: 2.031

4.  Treatment and Prognosis of Vogt-Koyanagi-Harada Disease: Real-Life Experience in Long-Term Follow-Up.

Authors:  Massimo Accorinti; Maria Carmela Saturno; Ludovico Iannetti; Priscilla Manni; Davide Mastromarino; Maria Pia Pirraglia
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

5.  Outcomes of Vogt-Koyanagi-Harada Disease: A Subanalysis From a Randomized Clinical Trial of Antimetabolite Therapies.

Authors:  Elizabeth Shen; Sivakumar R Rathinam; Manohar Babu; Anuradha Kanakath; Radhika Thundikandy; Salena M Lee; Erica N Browne; Travis C Porco; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2016-06-10       Impact factor: 5.258

6.  Aminoimidazole carboxamide ribonucleotide ameliorates experimental autoimmune uveitis.

Authors:  Jun Suzuki; Takeru Yoshimura; Marina Simeonova; Kimio Takeuchi; Yusuke Murakami; Yuki Morizane; Joan W Miller; Lucia Sobrin; Demetrios G Vavvas
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-28       Impact factor: 4.799

7.  Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease.

Authors:  Tatsushi Kawaguchi; Shintaro Horie; Nadia Bouchenaki; Kyoko Ohno-Matsui; Manabu Mochizuki; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2009-01-17       Impact factor: 2.031

8.  Dietary Omega-3 Fatty Acids Suppress Experimental Autoimmune Uveitis in Association with Inhibition of Th1 and Th17 Cell Function.

Authors:  Hiromi Shoda; Ryoji Yanai; Takeru Yoshimura; Tomohiko Nagai; Kazuhiro Kimura; Lucia Sobrin; Kip M Connor; Yukimi Sakoda; Koji Tamada; Tsunehiko Ikeda; Koh-Hei Sonoda
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

9.  Unique clinical spectrum with distinguishing diagnostic features in Vogt-Koyanagi-Harada syndrome.

Authors:  Mamoona Sultan; Adeena Khan; Syed Shahid Habib; Dheyab Abdulsalam
Journal:  BMJ Case Rep       Date:  2019-12-29

Review 10.  Gender differences in vogt-koyanagi-harada disease and sympathetic ophthalmia.

Authors:  Yujuan Wang; Chi-Chao Chan
Journal:  J Ophthalmol       Date:  2014-03-05       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.